Detalles de la búsqueda
1.
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Blood
; 127(15): 1896-906, 2016 Apr 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-26755711
2.
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Blood
; 127(25): 3165-74, 2016 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-27118453
3.
Bendamustine, bortezomib and prednisone for the treatment of patients with newly diagnosed multiple myeloma: results of a prospective phase 2 Spanish/PETHEMA trial.
Haematologica
; 100(8): 1096-102, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-25911554
4.
High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma.
Blood
; 119(3): 687-91, 2012 Jan 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-22128143
5.
Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials.
Am J Pathol
; 181(5): 1870-8, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22974582
6.
Mutational screening of newly diagnosed multiple myeloma patients by deep targeted sequencing.
Haematologica
; 103(11): e544-e548, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-29954938
7.
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study.
Lancet Haematol
; 4(8): e350-e361, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28712941
8.
Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials.
J Clin Oncol
; 35(25): 2900-2910, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28498784
Resultados
1 -
8
de 8
1
Próxima >
>>